好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Hidden Problems in Multiple Sclerosis: Gaps Between Patient Experience and Outcome Assessments
Multiple Sclerosis
P7 - Poster Session 7 (5:00 PM-6:00 PM)
1-003
The aim of the study was to identify hidden problems of Multiple Sclerosis (MS) via a literature review and evaluate whether existing clinical outcome assessments (COAs) adequately assess them. 
MS clinical practice and research focus on relapses, physical disability progression, and imaging. However, meaningful symptoms and quality of life (QoL) impacts experienced by people with MS (PwMS) may be overlooked and are not well understood or assessed. 

A concept-focused literature review was conducted via PubMed to identify qualitative, patient-centered research, such as focus groups, interviews, surveys focusing on limitations and QOL impacts experienced by PwMS. A total of 225 abstracts were screened, 34 were selected for full article review, and 12 ultimately included for concept extraction. Hidden problems were defined as symptoms and QoL impacts beyond relapses and disability as measured by Expanded Disability Status Scale (EDSS), and were organized by domain into a conceptual model. A gap analysis was performed to assess whether COAs used in MS include the identified concepts.

Almost 100 concepts were extracted covering function (n=5 domains; cognition, energy/sleep, sexual, emotional, physical), daily life (n=4 domains; relationships, social life, work, daily activities) and sense of self (n=2 domains; self-efficacy, adaptive behaviour). No MS COA comprehensively assess all domains. MS Impact Scale (MSIS-29) and Fatigue Severity Scale (FSS) only measure 3 and 1 domains respectively. MS Quality of Life Inventory (MSQLI) and MSQoL-54 are the most comprehensive, measuring seven domains each.

Existing COAs fail to capture the full disease experience of PwMS and therefore may not measure meaningful effect of MS therapies either. Existing COAs could be modified, or new tools created, to reflect the most salient hidden MS problems. An artificial intelligence (AI) approach combing holistic screening and assessment, could also address current gaps in measurement.

Authors/Disclosures
Andreas Lysandropoulos (Parexel)
PRESENTER
Andreas Lysandropoulos has nothing to disclose.
Naomi Suminski (Parexel) Naomi Suminski has received personal compensation for serving as an employee of Parexel.
Tjalf Ziemssen, MD, FAAN (University Clinic Dresden) Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS . Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Dresden Internation University. The institution of Dr. Ziemssen has received research support from Novartis. The institution of Dr. Ziemssen has received research support from Merck. The institution of Dr. Ziemssen has received research support from Sanofi. The institution of Dr. Ziemssen has received research support from BMS. The institution of Dr. Ziemssen has received research support from Roche.